Your Search Returned 59 tagged news reports
It had hit all-time highs in nine of the last 10 sessions and, on Thursday, the index did something unconventional: It took a step back. Perhaps it was warranted, as new housing starts slipped big-time in April (more than 16%), and recent industrial
Health Canada is warning people taking a thalidomide drug that users may be at risk of developing blood clots in their arteries. The warning was issued about the drug Thalomid, which is used in people aged 65 and older as a treatment for a blood
Hot Biotech Stocks to Buy Now Which biotech stocks should investors take a hard look at buying now? Health care analyst Max Macaluso sat down with Fool.com contributor Keith Speights recently to find out which stocks he likes in the biotech sector.
may offer well-known personal care products such as Listerine and Neutrogena, but it also boasts an impressive portfolio of market leading therapeutic compounds. The health care leader was one of the few to show growth in both worldwide
Pomalyst, the third drug in a class of immunomodulatory agents including lenalidomide and thalidomide, adjusts immune system of the body to destroy and inhibit the growth of cancerous cells. The drug is indicated for patients in whom the disease
Patients must have received at least two prior therapies including Revlimid and Velcade and show progression of the disease. What it means The immediate impact of the FDA decision is that Pomalyst will hit the market over the next few weeks. Celgene'
Source Newsroom: Newswise Researchers at Moffitt Cancer Center and colleagues have investigated the safety, efficacy and the maximum tolerated dose of pomalidomide for patients with multiple myeloma who have disease relapsed after treatments with
Before we hone in on the epigenetic drugs, let's look at the bigger picture. Celgene is a biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies to treat cancer and immune-inflammatory related
Since we looked at Pharmacyclics last year , the company has seen its score rise by three points, as revenue has soared and the company became profitable. The stock has also more than quadrupled in price over the past year. Pharmacyclics is a tiny
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...So what: Revenue came in at $16.8 million, well above the Street's